Hematologic Oncology | Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2020 ASH Annual Meeting

published 5 months ago by Dr Neil Love

Featuring an interview with Dr Aaron T Gerds on the following topics: Biologic rationale for the use of JAK inhibitors; key data supporting the FDA approval of ruxolitinib and fedratinib for myeloproliferative neoplasms (MPN) (0:00) Real-world survival among patients with intermediate- to high-risk myelofibrosis (MF) in the United States: Impact of ruxolitinib approval (3:09) Effect of ruxolitinib for inadequately controlled polycythemia vera (PV) without splenomegaly: Five-year results from the Phase III RESPONSE-2 study (5:27) Long-term safety of fedratinib for patients with intermediate- or high-risk MF (8:31) Activity and tolerability of momelotinib in patients with MF (11:37) Choice of JAK inhibitor for patients with MF (15:38) Risks and benefits with fedratinib for patients with MF who experience disease progression on ruxolitinib (23:05) Clinical experience with fedratinib in the treatment of MF (26:12) Improvement in survival outcomes, symptoms and quality of life with JAK inhibitors (34:33) Activity and tolerability of the telomerase inhibitor imetelstat in patients with intermediate 2- or high-risk MF that is relapsed or refractory to JAK inhibitors (39:16) Navitoclax with ruxolitinib in different populations of patients at high risk with relapsed/refractory MF (46:35) Role of ruxolitinib in therapy for patients with essential thrombocythemia and PV; effect of the hepcidin mimetic PTG-300 on treatment for PV (55:14) Efficacy of eprenetapopt (APR-246), a small molecule reactivator of mutant and inactivated p53, for myelodysplastic syndromes (MDS) with TP53 mutation (59:44) Hypomethylating agents in combination with venetoclax for elderly patients with acute myeloid leukemia (AML) (1:01:43) Benefits and risks of CPX-351 for patients with AML (1:08:21) Ongoing investigation of the oral combination of decitabine and cedazuridine for AML (1:10:30) Perspective on CC-486 (oral azacitidine) as maintenance therapy for patients with AML (1:13:08) Role of luspatercept for the treatment of anemia associated with MDS (1:16:01) CME information and select publications

more episodes from Research To Practice | Oncology Videos